A look at the local numbers
Public Health Sudbury & Districts is reporting two new cases of COVID-19, both in Greater Sudbury.
Considering resolved cases, there are 19 active cases within the agency’s jurisdiction.
Health Sciences North states it has 13 admitted patients, two who have tested positive and 11 waiting for test results.
Of the two, one individual is in intensive care.
Algoma Public Health has had no new cases in the last four days.
Considering resolved cases, there are three active cases in the district.
The one individual in hospital is not from the district but is receiving treatment locally.
Provincially, Ontario added 370 new COVID-19 cases yesterday (Thursday).
It was the eleventh straight day cases have been below 600.
The recovery rate is steady at 97 per cent with more recoveries than new cases reported.
AstraZeneca not recommended as a second dose
Canadians who got a first shot of AstraZeneca are now being advised to get a second shot of Pfizer or Moderna, known as an mRNA vaccine.
The recommendation comes from the National Advisor Committee on Immunization which says a mixed dose of AstraZeneca and an mRNA vaccine will provide greater immunization against COVID-19.
As well as having better inoculation against the virus NACI says there is a risk of developing a rare blood clot after a second shot of AstraZeneca.
Since May, provinces have stopped giving AstraZeneca as a first shot but have continued to provide it as a booster shot.
Pressure to reopen border
Pressure continues to mount on the federal government to loosen border restrictions to fully vaccinated travellers.
Both Canadian and American tourism groups want the land border reopened quickly.
The groups say tens of thousands of jobs are at risk and an entire second tourism season could be lost.
The Canadian government is poised to make an announcement before the border closure to non-essential travel expires on Monday.
PHOTO: Canadians who got a first shot of AstraZeneca are now being advised to get a second shot of Pfizer or Moderna, known as an mRNA vaccine. Photo provided by AstraZeneca